Beta Bionics (BBNX) Cost of Revenue (2024 - 2026)

Beta Bionics has disclosed Cost of Revenue across 3 years of filings, most recently posting $13.1 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 22.13% year-over-year to $13.1 million; the TTM figure through Jun 2026 stood at $49.6 million (up 38.02% YoY), while the FY2025 annual figure was $44.7 million, up 52.94% from the prior year.
• Cost of Revenue came in at $13.1 million for Q2 2026 at Beta Bionics, up from $11.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $13.2 million in Q4 2025 to a low of $5.7 million in Q1 2024.
• Average Cost of Revenue over 3 years is $9.8 million, with a median of $9.7 million recorded in 2024.
• Year-over-year, Cost of Revenue jumped 55.74% in 2025 and gained 22.13% in 2026.
• Over 3 years, Cost of Revenue stood at $8.8 million in 2024, then surged by 50.58% to $13.2 million in 2025, then retreated by 0.5% to $13.1 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $13.1 million in Q2 2026, $11.2 million in Q1 2026, and $13.2 million in Q4 2025.